Universität zu Köln

Journal Article

Roemer, Margaretha G. M., Redd, Robert A., Cader, Fathima Zumla, Pak, Christine J., Abdelrahman, Sara, Ouyang, Jing, Sasse, Stephanie, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John, Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Ansell, Stephen, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Sumbul, Anne, Armand, Philippe, Neuberg, Donna S., Pinkus, Geraldine S., Ligon, Azra H., Rodig, Scott J. and Shipp, Margaret A. (2018). Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J. Clin. Oncol., 36 (10). S. 942 - 954. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Armand, Philippe, Engert, Andreas, Younes, Anas, Fanale, Michelle, Santoro, Armando ORCID: 0000-0003-1709-9492, Zinzani, Pier Luigi, Timmerman, John M., Collins, Graham P., Ramchandren, Radhakrishnan, Cohen, Jonathon B., De Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trneny, Marek, Shipp, Margaret A., Kato, Kazunobu, Sumbul, Anne, Farsaci, Benedetto ORCID: 0000-0001-8275-2561 and Ansell, Stephen M. (2018). Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J. Clin. Oncol., 36 (14). S. 1428 - 1450. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John, Ansell, Stephen Maxted, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon Brett, Collins, Graham P., Savage, Kerry J., Trneny, Marek, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott J., Shipp, Margaret Ann and Engert, Andreas (2016). Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) A phase 2 study. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Roemer, Margaretha G. M., Ligon, Azra H., Engert, Andreas, Younes, Anas, Santoro, Armando, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle A., Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham P., Savage, Kerry J., Trneny, Marek, Neuberg, Donna S., Redd, Robert A., Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Kato, Kazunobu, Sumbul, Anne, Rodig, Scott J. and Shipp, Margaret A. (2016). Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Younes, Anas, Santoro, Armando ORCID: 0000-0003-1709-9492, Shipp, Margaret, Zinzani, Pier Luigi, Timmerman, John M., Ansell, Stephen, Armand, Philippe, Fanale, Michelle, Ratanatharathorn, Voravit, Kuruvilla, John, Cohen, Jonathon B., Collins, Graham ORCID: 0000-0002-8803-4234, Savage, Kerry J., Trneny, Marek ORCID: 0000-0002-6952-6073, Kato, Kazunobu, Farsaci, Benedetto ORCID: 0000-0001-8275-2561, Parker, Susan M., Rodig, Scott, Roemer, Margaretha G. M., Ligon, Azra H. and Engert, Andreas (2016). Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol., 17 (9). S. 1283 - 1295. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488